A new review identifies three fibroblast-driven mechanisms that make liver cancer cells resistant to kinase inhibitors and ...

Tens of thousands of people are demanding that the Government stops plans to add acid to a common food product consumed by ...

The investigational drug rinatabart sesutecan (Rina-S) shrank tumors in 45.9% of patients with platinum-resistant ovarian ...

In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.

Children, Families, and the 2026 Revised Blood Guidance for Jehovah's Witnesses - An Update for Pediatric Hematology and ...

An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no ...

A new zebrafish study links hyperglycemic retinal angiogenesis to the folate-dependent thymidylate cycle and shows that ...

Stay full longer with these high-protein, high-fiber foods, from lentils and edamame to chia seeds and black beans, plus ...

Saying that garland chrysanthemum is just about vitamins is a thing of the past.Recent research has shown its power to strengthen bones and prevent blood vessel oxidation.In this article, I will ...

Phase 1/2 RAINFOL-01 data show a 45.9% objective response rate and 12.1-month median duration of response, with antitumour activity observed regardless of FRα expression levels. Treatment with Rina-S ...

Rina-S delivered a 46% confirmed response rate and durable responses lasting 12 months in platinum-resistant ovarian cancer.

Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients with platinum-resistant ovarian cancer.